Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bard completes takeover of SenoRx

Bard completes takeover of SenoRx

8th July 2010

Bard has announced that it has completed its move to acquire the breast cancer specialist SenoRx after purchasing all shares in the company.

The deal, which was originally announced in May 2010, has been valued at approximately $200 million (131.9 million pounds) and sees SenoRx become a part of Bard’s peripheral vascular division.

SenoRx is based in the US and is responsible for a wide variety of medical devices for breast cancer applications, including the EnCor range of breast biopsy systems and the Contura balloon catheter product.

According to Bard’s statement in May, the deal has been initiated in order to allow the firm to expand its business into the breast biopsy market.

Timothy Ring, chairman and chief executive officer of Bard, said: “The SenoRx acquisition represents a very compelling strategic opportunity for Bard, enabling us to provide customers leadership products across all breast biopsy and marker segments.”

According to Bard’s most recent financial report, the company saw a nine per cent year-on-year increase in sales during the first quarter of this year.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.